Empresas SB
Date: Jun 2019
Client: Empresas SB
Counterparty: Eurofarma
Industry: Healthcare
Amount: Undisclosed amount
Transaction:
Financial advisor to Empresas SB on the sale of Medipharm, the group's only pharmaceutical laboratory, to Brazilian laboratory Eurofarma.
Medipharm markets more than 140 pharmaceuticals, mainly in the neurological, respiratory and gastrointestinal categories. In 2017, it inaugurated its state-of-the-art pharmaceutical plant in Santiago’s Pudahuel district, with 13,700 m2 and a production capacity of 1.3 million units per month.
Empresas SB is a specialized group dedicated to deliver a wide range of products and services in the field of health and beauty. Composed of ten subsidiaries, including Chile’s second largest pharmacy chain Farmacias Salcobrand, has approximately 10,000 employees and 600 points of sale throughout the country.
Established in 1972, Eurofarma is one of the largest pharmaceutical companies in Brazil. With operations in more than 20 countries in South and Central America, the Caribbean and Africa, and 9 manufacturing plants strategically located in Latin America, Eurofarma is positioned in the major pharmaceutical segments: Medical Prescription and OTC, Generics, Hospital, Bidding, Oncology, Third Party Services and Veterinary. The company has a broad portfolio that meets all medical specialties, and which is a reference in the central nervous system, anti-infective and hormonal drugs.
Jun 2019
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/empresas%20sb.png?width=130&height=48&name=empresas%20sb.png)
on the sale of Medipharm to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/eurofarma.png?width=130&height=48&name=eurofarma.png)
Undisclosed amount
Similar transactions
Nov 2021
![](https://landmark-cap.com/hs-fs/hubfs/Banderas%20Pa%C3%ADses/bandera_francia.jpg?width=27&height=18&name=bandera_francia.jpg)
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/centrovet.png?width=130&height=48&name=centrovet.png)
on the sale of 34% of the shares to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/virbac.jpg?width=130&height=48&name=virbac.jpg)
With this transaction, Virbac completes the acquisition of 100% of the company since the initial purchase in 2012
Leer más